---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-24-000106"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:44:37.352757+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Integra Q3 revenue down 0.4%, GAAP EPS loss; lowers FY2024 guidance; appoints new CEO

## Summary
- Revenue $380.8M, down 0.4% reported and 8.6% organic; GAAP EPS $(0.14) vs $0.24, adjusted EPS $0.41 vs $0.76.
- Neurosurgery organic sales -16% on shipping holds; Instruments +8.7%; Tissue Tech -3.7% organic, ex-Boston -9.4%.
- FY2024 revenue guidance lowered to $1.609-1.619B (organic -1.7% to -1.0%); adjusted EPS guided $2.41-$2.49.
- Mojdeh Poul named next president and CEO, effective Jan 6, 2025, succeeding retiring Jan De Witte.
- Shipping holds releasing in line with expectations; Integra Skin production on pace for Q4 historical run rates.

## SEC filing metadata
- accession: 0000917520-24-000106
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752024000106/0000917520-24-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752024000106/iart-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-24-000106
- JSON: https://secwatch.observer/filing/0000917520-24-000106.json
- Plain text: https://secwatch.observer/filing/0000917520-24-000106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.